Toggle Side Panel
AIiHC ORG
  • Home
  • About Us

    Our Story

  • Community

    1. Stakeholder Connect

    1.1 Clinician's forum

    1.2 Healthcare leaders

    1.3 AI Innovators & Developers

    1.4 Policy, Regulatory experts

    1.5 IT & Infrastructure Management

    1.6 Industry & Solution Providers

    1.7 Patients & Caregivers

    2. AI Adoption cycle

    2.1 Exploration and Readiness

    2.2 Implementation & Integration

    2.3 Monitoring & Optimization

    2.4 Future & Emerging AI

    3. Ethics & Governances

    3.1 Ethical AI & Fairness

    3.2 Data Governance & Security

    3.3 Regulatory Landscape

    3.4 Standards and Best Practices

    4. Clinical Domains

    4.1 Medical AI

    4.2 Surgical AI

    4.3 Diagnostic Imaging AI

    4.4 Primary Care & Family Medicine

    4.5 Medical and Behavioural Health

    4.6 Drug Discovery & Pharma

    4.7 Public & Population Health

    4.8 Hospital System Operations

    5. Academics

    5.1 Research Project Collaboration

    5.2 Grant & Funding Opportunities

    5.3 Clinical Trials & Academic Studies

    5.4 University & Institution Connect

    5.5 Research Methodologies & Tools

    5.6 Education & Workforce development

    6. Industry Exchange

    6.1 AI Application Vendors

    6.2 Platform & Infrastructure Providers

    6.3 Implementation & Consultancy Partners

    6.4 MedTech, Pharma & Device Innovators

    6.5 Responsible Industry Practices

  • Discussions
  • Contact us
More options
    Sign in
    • Home
    • About Us
    • Community
      • 1. Stakeholder’s Connect
        • 1.1 Clinician’s forum
        • 1.2 Healthcare leaders
        • 1.3 AI Innovators & Developers
        • 1.4 Policy, Regulatory experts
        • 1.5 IT & Infrastructure Management
        • 1.6 Industry & Solution Providers
        • 1.7 Patients & Caregivers
      • 2. AI Adoption Cycle
        • 2.1 Exploration and Readiness
        • 2.2 Implementation & Integration
        • 2.3 Monitoring & Optimization
        • 2.4 Future & Emerging AI
      • 3. Ethics & Governance
        • 3.1 Ethical AI & Fairness
        • 3.2 Data Governance & Security
        • 3.3 Regulatory Landscape
        • 3.5 Standards and Best Practices
      • 4. Clinical Domains
        • 4.1 Medical AI
        • 4.2 Surgical AI
        • 4.3 Diagnostic Imaging AI
        • 4.4 Primary Care & Family Medicine
        • 4.5 Medical and Behavioural Health
        • 4.6 Drug Discovery & Pharma
        • 4.7 Public & Population Health
        • 4.8 Hospital System Operations
      • 5. Academics
        • 5.1 Research Project Collaboration
        • 5.2 Grant & Funding Opportunities
        • 5.3 Clinical Trials & Academic Studies
        • 5.4 University & Institution Connect
        • 5.5 Research Methodologies & Tools
        • 5.6 Education & Workforce development
      • 6. Industry Exchange
        • 6.1 AI Application Vendors
        • 6.2 Platform & Infrastructure Providers
        • 6.3 Implementation & Consultancy Partners
        • 6.4 Medtech, Pharma & Device Innovators
        • 6.5 Responsible Industry Practices
    • Discussions
    • Contact us
    Close search
    Group logo of 4.6 | Drug Discovery & Pharma

    4.6 | Drug Discovery & Pharma

    Public AI in Clinical Domain

    Public AI in Clinical Domain

    Active 3 months ago

    Purpose: AI’s role in accelerating drug development, from target identification to clinical trial... View more

    Public AI in Clinical Domain

    Organizer:

    Organized by
    • Profile photo of AIiHC

    Group Description

    Purpose: AI’s role in accelerating drug development, from target identification to clinical trial optimization.

    Description: This group explores how AI and machine learning are transforming the pharmaceutical industry, enhancing efficiency and success rates across the entire drug discovery and development pipeline.

    Intended Use: For pharmaceutical researchers, drug developers, AI developers, and academics to discuss specific AI algorithms and strategies impacting drug design, preclinical research, clinical trials, and drug repurposing.

    Limitations: Not for general AI model development (that’s 1.3). Not for direct patient care applications. Focus is on AI within the pharmaceutical and drug discovery domain.

    Key Activities:Sharing breakthroughs in AI-driven target identification.Discussing AI’s impact on optimizing clinical trial design and patient selection.Exploring AI for drug repurposing and accelerating R&D.Debating ethical considerations in AI-accelerated drug development.

    Potential Users: Academic/Researcher, AI Innovator/Developer, Industry/Solution Provider (Pharma/Biotech).

    Possible Discussions: “Using AI to identify novel drug targets for oncology,” “AI-powered prediction of drug toxicity,” “The role of AI in accelerating vaccine development.”

    Leave Group

    Are you sure you want to leave ?

    Cancel Confirm
    • Subgroups
    • Feed
    • Members
    • Documents
    • Discussions

    Loading groups of the community. Please wait.

    © 2025 - AI Healthcare Community
    • Disclaimer
    • Rules And Regulation
    • Community Guidelines
    • Terms of Use
    • Privacy Policy

    Report

    There was a problem reporting this post.

    Harassment or bullying behavior
    Contains mature or sensitive content
    Contains misleading or false information
    Contains abusive or derogatory content
    Contains spam, fake content or potential malware

    Block Member?

    Please confirm you want to block this member.

    You will no longer be able to:

    • See blocked member's posts
    • Mention this member in posts
    • Invite this member to groups
    • Message this member
    • Add this member as a connection

    Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

    Report

    You have already reported this .